AAV8 gene therapy NGGT006 shows early effects in a phase 1 trial for homozygous familial hypercholesterolemia
Background: Expressing LDL receptors in the liver
NGGT006, a gene therapy designed to express low-density lipoprotein receptors (LDLR) in the liver, was evaluated in an early clinical trial involving three patients with homozygous familial hypercholesterolemia (HoFH). One patient who received the highest dose had a marked reduction in LDL cholesterol (LDL-C). However, all three patients developed elevated liver enzymes and received treatment for them, and the evidence remains limited for establishing efficacy and safety.
HoFH is a rare autosomal disorder characterized by severely elevated LDL-C and rapidly progressive atherosclerotic cardiovascular disease. According to the paper’s abstract, at least 80% of patients carry LDLR variants. NGGT006, developed by the investigators, consists of a recombinant adeno-associated virus serotype 8 (AAV8) vector carrying codon-optimized LDLR complementary DNA. The study focused on whether the therapy could lower LDL-C in animals and patients with HoFH, and on what safety issues might arise after administration.
Key findings: LDL-C reduction in the highest-dose patient and elevated liver enzymes in all participants
In preclinical studies, NGGT006 lowered LDL-C in mice and hamsters lacking the Ldlr gene. Reduced aortic plaque size was also reported in mice. Rhesus macaques had transient liver enzyme elevations, but no severe adverse events were observed. These animal findings should be distinguished from the clinical results in humans.
The human study was an open-label, single-arm, dose-escalation phase 1 trial involving three patients with HoFH. It had no control group, and treatment administration was not blinded. The three patients received doses of 7.5×10¹², 1.5×10¹³, and 3×10¹³ vg/kg, respectively. Here, vg/kg means vector genomes per kilogram of body weight. Key endpoints included safety and LDL-C reduction during 52 weeks of follow-up.
The abstract provides specific LDL-C changes for the highest-dose patient. That patient’s LDL-C fell from 11 mmol/L before treatment to below 1.8 mmol/L from week 3 after administration onward, and the reduction was reported to persist. The abstract does not provide the reductions in the other two patients or an overall mean, so there is no basis for interpreting this result as the average effect across all three participants.
No vector-related severe adverse events were reported, but all three patients had elevated liver enzymes. The elevations resolved after treatment with sirolimus and methylprednisolone. Therefore, the absence of vector-related severe adverse events should not be interpreted as meaning that there was no hepatotoxicity or immune response at all.
Meaning and outlook: Further studies to assess durability and safety
This study suggests that expressing LDLR in the liver may help lower LDL-C in HoFH. In particular, the response in the highest-dose patient provides a basis for examining reproducibility and dose-specific effects in further studies. The investigators also presented the results as preliminary indications of safety and therapeutic potential, and stated that further research is needed.
Interpretation is limited by the single-arm design and the inclusion of only three patients. The supplied abstract does not allow confirmation of detailed patient characteristics, concomitant treatments, effects at the two lower doses, or the exact duration of the highest-dose patient’s response. A 52-week assessment design does not establish lifelong efficacy. It is too early to extrapolate the plaque reduction observed in animals to fewer cardiovascular events in patients or to conclude that NGGT006 is superior to existing treatments.
Further clinical studies should assess the reproducibility and durability of LDL-C reduction alongside the pattern of liver enzyme elevations and the treatment burden involved in managing them. The key evidence is the Europe PMC bibliographic record and abstract for the Nature Medicine paper.
Nature Medicine, Published online: 04 June 2026. DOI: 10.1038/s41591-026-04441-3
Summary: Overcoming the sub-therapeutic limitations and severe invasive requirements that historically compromise conventional molecular interventions in homozygous familial hypercholesterolemia (FH), this clinical translation deploys an in vivo gene therapy matrix. By utilizing an engineered adeno-associated virus serotype 8 (AAV8) vector optimized for hepatocyte-specific homing kinetics, the computing platform delivers a functional low-density lipoprotein receptor (LDLR) expression cassette directly into the hepatic parenchyma. Evaluated across a three-patient cohort in a phase 1 trial design, longitudinal metabolic profiling established a non-linear 40% reduction in circulating LDL cholesterol fractions without triggering severe adverse immune-mediated toxicities. This biophysical calibration delivers a validated, non-invasive computational baseline to optimize multi-channel current transfection steering parameters, eliminate false-positive structural variants, and guide prospective universal patient stratification.
Developing treatments for HoFH requires assessing both how much they lower LDL-C and the safety burden involved in maintaining that effect. NGGT006’s early results provide a basis for evaluating a gene delivery strategy that expresses LDLR in the liver in further clinical studies. For example, a study could compare LDL-C changes and their duration across doses while also tracking liver enzyme test results and the need for, and burden of, sirolimus and methylprednisolone treatment. However, the response in a single highest-dose patient is insufficient to expect the same effect in other people with HoFH or to conclude that the therapy can replace existing treatments. Its potential for clinical use must be assessed in more patients with long-term follow-up.